Peptara LabsPEPTARA LABS

Head to head

BPC-157 vs TB-500: Gut vs Muscle Repair

A side-by-side comparison of the two recovery peptides most often stacked together: mechanism, injury type, dosing in units, side effects, monthly cost, and the KLOW Combo stack option. Both BPC-157 and TB-500 are research compounds, not FDA-approved for any indication.

Verdict in 4 lines

  • Both are research peptides used for tissue repair.
  • BPC-157 excels at gut, tendon, and ligament healing through pro-angiogenic and cytoprotective mechanisms.
  • TB-500 excels at muscle and deep-tissue repair through actin sequestration and cell migration.
  • Most users stack both, which is why Peptara offers the KLOW Combo (BPC + TB-500 + GHK-Cu + KPV in one vial).

TL;DR comparison

One table, every row that matters. Doses use units from a U-100 insulin syringe with the Peptara standard reconstitutions (BPC 20mg in 2mL bac water, TB-500 10mg in 1mL bac water; both give 0.1mg per unit). See the reconstitution guide for the underlying math.

BPC-157
TB-500
Class
Pentadecapeptide fragment (15 aa)
Thymosin beta-4 fragment (7 aa active site)
Mechanism
Pro-angiogenic + cytoprotective
Actin-sequestering + cell migration
Best for
Gut, tendon, ligament, joint repair
Muscle, deep soft-tissue, systemic repair
FDA status
Research compound (not FDA-approved)
Research compound (not FDA-approved)
Research base
Sikiric et al published rodent series
Limited human data, more athlete anecdote
Vial size sold by Peptara
20mg
10mg
Standard recon
2mL bac water gives 200u/vial, 0.1mg/u
1mL bac water gives 100u/vial, 0.1mg/u
Typical dose
250 to 500mcg = 3 to 5u, 1 to 2x daily
2mg = 20u, 2x weekly loading then 1x weekly
Cycle length
4 to 8 weeks then off
4 weeks loading then maintenance or off
Cost at typical dose
about $89 to $177/mo first-time
about $162 to $324/mo first-time (loading higher)
Stack-together version
Both in KLOW Combo (1 vial)
Both in KLOW Combo (1 vial)

Mechanism: pro-angiogenic vs actin-sequestering

Both peptides accelerate tissue repair, but they reach that outcome through different molecular routes. The non-overlap is what makes them so commonly stacked.

BPC-157 (pro-angiogenic)

A 15-amino-acid fragment derived from a protective gastric juice peptide. Promotes blood vessel growth (angiogenesis) at the injury site, protects against inflammation, and accelerates fibroblast migration. The strongest published evidence is in rodent models of gut, tendon, and ligament injury (Sikiric et al series).

View BPC-157 product

TB-500 (actin-sequestering)

A synthetic fragment of thymosin beta-4, the body\u2019s endogenous regulator of actin polymerization. Binds and sequesters G-actin, which controls how migrating cells move into a wound bed. Active in muscle repair, wound healing, and anti-fibrotic processes. Human evidence is more limited than BPC; much of it is athlete anecdote and case reports.

The mechanisms layer rather than compete. BPC builds the vasculature and dampens inflammation; TB-500 migrates the right cells to the right place. That non-redundancy is why a four-week BPC + TB-500 stack is so common after acute injuries that involve both connective tissue and muscle.

Which one for which injury type

A short routing guide. Most chronic multi-tissue cases end up stacking both anyway.

BPC-157 first-line

  • Gut issues (IBD-type symptoms, leaky gut)
  • Tendinopathy (golfer-elbow, patellar tendon)
  • Ligament sprains
  • Joint pain
  • Skin healing, cuts, surgical scars

TB-500 first-line

  • Muscle tears, strains, deep bruising
  • Post-surgical recovery (muscle bias)
  • Chronic muscle pain
  • Systemic fatigue with soft-tissue component
  • Athletes in heavy training blocks

Stack both

  • Chronic multi-tissue injuries
  • Athletes in heavy training blocks
  • Post-surgical with muscle + connective involvement
  • Complex injuries that did not resolve on a single peptide

Research evidence

What is published, what is anecdotal, and the disclaimer that has to come with both.

BPC-157 evidence base

The largest body of published preclinical data comes from the multi-decade Sikiric et al rodent series, covering gastric ulcer healing, tendon-to-bone reattachment, ligament repair, and CNS effects. Smaller groups have replicated parts of the gut and tendon findings. Human controlled trials are limited and small. The peptide community references the rodent literature heavily.

TB-500 evidence base

Thymosin beta-4 (the parent molecule) has a real research literature in cardiac remodeling and wound healing. TB-500 specifically (the synthetic 7-amino-acid active fragment) has fewer controlled studies; most of its user-facing reputation comes from veterinary use (racehorses) and athlete case reports. As a result, the dosing protocols are more anecdotal than the BPC protocols.

Regulatory disclaimer

BPC-157 and TB-500 are both classified as research compounds in most jurisdictions. Neither is FDA-approved for any indication. The mechanisms and use cases described on this page come from preclinical research, peptide community case reports, and athlete anecdote, not from large randomized clinical trials. Peptara Labs sells both as research material with Certificates of Analysis available on request.

Side effects

Both have minimal reported side effects in the user-dose ranges Peptara sells. Notes below are not exhaustive.

Shared

  • Mild fatigue during first week of a new dose step
  • Occasional injection-site irritation
  • Titrate slowly, rotate injection sites

BPC-157 specific

  • Occasional injection-site irritation
  • Mild GI changes at high oral doses (rare for subQ users)
  • Generally well tolerated at 250 to 500mcg subQ daily

TB-500 specific

  • Theoretical concerns about cell proliferation at extreme doses
  • No documented human cases at typical user doses
  • WADA-banned in competitive sport: check sport-specific regulations

Dosing protocols (units, not mL)

Both peptides hit 0.1mg per unit at the Peptara standard reconstitution (BPC 20mg in 2mL bac water; TB-500 10mg in 1mL bac water). See /reconstitution for the underlying U-100 math (1 unit equals 0.01mL on an insulin syringe).

BPC-157 typical

20mg vial, 200u total, 0.1mg/u

  • 250mcg per injection: 3 units (rounded from 2.5u)
  • 500mcg per injection: 5 units
  • Frequency: 1 to 2 injections daily, near injury site or systemic subQ
  • Cycle: 4 to 8 weeks then 2 to 4 weeks off

TB-500 typical

10mg vial, 100u total, 0.1mg/u

  • Loading dose: 2mg = 20 units, 2x weekly for 4 weeks (about $324/mo first-time during loading)
  • Maintenance dose: 2mg = 20 units, 1x weekly (about $162/mo first-time)
  • Alternative: 4-week loading then off, no maintenance
  • Higher dose research protocol: 5mg = 50 units

The only mL number on this page is the bac water input volume (2mL for the 20mg BPC vial, 1mL for the 10mg TB-500 vial). Every dose is in units. Reading a decimal place wrong on a small syringe barrel is the most common source of 10x overdoses, which is why protocol dashboards never display doses in mL.

Cost per month at Peptara prices

All numbers below use first-time customer pricing (with retail equivalent in parentheses) and are derived from the formula: cost per month equals vial price times 4.33 weeks per month, divided by weeks per vial.

Weeks per vial

weeks per vial = vial mg / weekly dose in mg

Example, BPC at 500mcg per day = 3.5mg per week. 20mg / 3.5mg = 5.71 weeks per vial. Monthly cost = $117 times 4.33 / 5.71 = about $89/mo first-time.

BPC-157

$117 first-time per 20mg vial ($138 retail)

  • 500mcg/day (typical): about $89/mo first-time, about $105/mo retail
  • 1mg/day (high-dose): about $177/mo first-time, about $209/mo retail

TB-500

$187 first-time per 10mg vial ($220 retail)

  • 2mg 1x/wk (maintenance): about $162/mo first-time, about $191/mo retail
  • 2mg 2x/wk (loading): about $324/mo first-time, about $381/mo retail

Stacked together

Both stacked separately at typical doses: about $251 to $413/mo first-time (BPC typical plus TB-500 loading combined). Both stacked via KLOW Combo: one 80mg vial contains BPC, TB-500, GHK-Cu, and KPV in proportional ratios at a single price point. Pricing depends on your dose schedule; see the KLOW Combo card on the homepage catalog for current pricing.

Should you stack them?

Unlike Retatrutide vs Tirzepatide where you typically pick one, BPC-157 vs TB-500 is not an adversarial decision. Many users run both. Peptara packages the stack as the KLOW Combo.

Pick BPC-157 alone if

  • Single localized injury, gut or tendon focused
  • Budget-tier recovery protocol
  • First peptide cycle, want to test response
  • Chronic gut issues (BPC has the gut data)

Pick TB-500 alone if

  • Muscle-only repair
  • Post-surgical bias toward muscle
  • Not budget-constrained
  • Already know your BPC response from a prior cycle

Run both via KLOW Combo

  • Multi-tissue injury (muscle + connective)
  • Athletes in heavy training blocks
  • Want one-vial convenience over two-vial complexity
  • Post-surgical with mixed tissue involvement

The KLOW Combo is an 80mg single vial containing BPC, TB-500, GHK-Cu, and KPV in proportional ratios. One injection delivers all four peptides. The point is consolidated cost and reduced injection count for users running a multi-tissue recovery protocol. See the homepage catalog for current KLOW pricing.

Frequently asked questions

Order recovery, get a weekly protocol dashboard

Order BPC-157, TB-500, or KLOW and we build your weekly recovery protocol dashboard within 12 hours.

Every order ships with bac water sized to the vial, a custom dashboard with your doses in units (never mL), and ongoing protocol support on WhatsApp.

Chat with us